The Scientific Review and Monitoring Committee (SRMC) provides the critical review of scientific merit, methodology and validity of statistical analyses of cancer-relevant studies prior to activation. The committee will ensure proper prioritization of studies and the ability to monitor all cancer-related studies for expected progress relating to accrual goals and performance standards.
The SRMC has the authority and charge to close any study not meeting the expected accrual goals or trials that have become obsolete by new advances in the field and therefore whose scientific rationale has become superseded by clinical practice. For a protocol to be reviewed by the SRMC, both the sponsoring Disease Site Group (DSG) and/or Research Program (RP) must provide endorsement.
Committee Decisions
Following discussion, the Committee votes to Approve, Approve with Stipulations, Table or Disapprove the protocol, meaning:
- Approved: Approved for opening to accrual contingent upon obtaining IRB approval and completion of all other protocol activation steps
- Approved with Stipulations: Study is approvable pending satisfactory responses to reviewer questions and concerns. The initial reviewers will review the PI response to stipulations, and the SRMC Chair or a Co-Chair will provide final approval.
- Tabled: Substantial issues are present and revisions and/or formal reconsideration by SRMC are required.
- Disapproved: The study is not approved for opening.
Important Documents
- SRMC Policies and Procedures Manual
- Low Accrual CAP Template
- Data and Safety Monitoring Plan
- Summary of Changes
- SRMC Feasibility Assessment Form
Contact
For information related to the SRMC, please contact the SRMC Administrative team at UFHCC-SRMC@ufl.edu.
Submission Deadlines for SRMC
The SRMC comprises two panels that each meet twice per month: the Biomedical Sciences Panel (BMSP) and the Cancer Control and Population Sciences Panel (CCPSP). The meetings are held virtually.
Frequently Asked Questions
SRMC BMSP Membership List
| name | role | specialty/expertise |
|---|---|---|
| Ryan M. Thomas, M.D. | Chair | GI Surgery and Microbiome Biorepository |
| Tithi Biswas, M.D. | Core | Radiation Oncology; Thoracic; Breast |
| David DeRemer, Pharm.D. | V-Chair | Pharmacodynamics & Drug Development |
| Aline Fares, M.D. | Core | Medical Oncology; Thoracic |
| Samuel Jean-Baptiste, M.D. | Core | Radiation Oncology |
| Ji-Hyun Lee, DrPH | V-Chair | Biostatistics |
| Debra Lyon, Ph.D., R.N., FNP-BC, FNAP, FAAN | V-Chair | Cancer Prevention and Cancer Survivorship |
| Elias Sayour, M.D., Ph.D. | Core | Pediatric NeuroOnc |
| Coy Heldermon, M.D., Ph.D. | Core | Breast Oncology |
| Petr Starostik, M.D. | Core | Pathology & Genetics |
| Arkaprava Roy, Ph.D. | Core | Biostatistics |
| Muxuan Liang, Ph.D. | Core | Biostatistics |
| Karen Miller, JD | Core | Patient Advocate |
| Jennifer Woodard, M.P.H., R.N., CCRP | Core | Community Outreach and Engagement |
| Tuo Lin, Ph.D. | Core | Biostatistics |
| Padraic O’Malley, M.Sc., M.D., FRCSC | Core | Urologic Oncology |
| Serendipity Rinonos, M.D., Ph.D. | Core | Neuro-oncology |
| David Iglesias, M.D. | Core | Gynecologic Oncology |
| Sara Falzarano, M.D. | Core | Pathology |
| Ibrahim Nassour, M.D., MSCS | Core | Surgical Oncology |
SRMC CCPSP Membership List
| name | role | specialty/expertise |
|---|---|---|
| Debra Lyon, Ph.D., R.N., FNP-BC, FNAP, FAAN | Chair | Cancer Prevention and Cancer Survivorship |
| Stephen Anton, Ph.D. | Core | Psychology, Cancer Prevention |
| Yan Gong, Ph.D. | Core | Pharmacogenomics |
| Deidre Pereira, Ph.D., ABPP | Core | Psychosocial & Biobehavioral Interventions |
| Carma Bylund, Ph.D., FACH | Core | Survivorship |
| Ji-Hyun Lee, DrPH | Core | Biostatistics |
| Tuo Lin, Ph.D. | Core | Biostatistics |
| Arkaprava Roy, Ph.D. | Core | Biostatistics |
| Muxuan Liang, Ph.D. | Core | Biostatistics |
| Karen Miller, J.D. | Core | Citizen Scientist |
| Jennifer Woodard, M.P.H., R.N., CCRP | Core | Community Outreach and Engagement |
